86 related articles for article (PubMed ID: 10474088)
1. Isoantibodies in immunoglobulin for intravenous use may cause erythrocyte sequestration.
Shoham-Kessary H; Gershon H
Vox Sang; 1999; 77(1):33-9. PubMed ID: 10474088
[TBL] [Abstract][Full Text] [Related]
2. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration.
Kessary-Shoham H; Levy Y; Shoenfeld Y; Lorber M; Gershon H
J Autoimmun; 1999 Aug; 13(1):129-35. PubMed ID: 10441177
[TBL] [Abstract][Full Text] [Related]
3. Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes.
Reagan WJ; Scott-Moncrieff C; Christian J; Snyder P; Kelly K; Glickman L
Am J Vet Res; 1998 Dec; 59(12):1568-74. PubMed ID: 9858408
[TBL] [Abstract][Full Text] [Related]
4. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
Morgan S; Sorensen P; Vercellotti G; Zantek ND
Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
[TBL] [Abstract][Full Text] [Related]
5. Chemical treatment of anti-D results in improved efficacy for the inhibition of Fcgamma receptor-mediated phagocytosis.
Foo AH; Ramkumar S; Helke S; Branch DR
Transfusion; 2007 Dec; 47(12):2250-9. PubMed ID: 17714414
[TBL] [Abstract][Full Text] [Related]
6. Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes.
Shoham-Kessary H; Naot Y; Gershon H
Clin Exp Immunol; 1998 Jul; 113(1):77-84. PubMed ID: 9697987
[TBL] [Abstract][Full Text] [Related]
7. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations.
Sakem B; Matozan K; Nydegger UE; Weigel G; Griesmacher A; Risch L
Isr Med Assoc J; 2013 Oct; 15(10):617-21. PubMed ID: 24266088
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin-induced panel reactive antibody A reduction: not all preparations are created equal.
Clark B; Cole JY; Wortley A; Toolan J; Stoves J; Newstead CG; Gooi HC
Transplantation; 2003 Jan; 75(2):242-5. PubMed ID: 12548133
[TBL] [Abstract][Full Text] [Related]
9. Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura.
Aubin E; Lemieux R; Bazin R
Br J Haematol; 2007 Mar; 136(6):837-43. PubMed ID: 17341270
[TBL] [Abstract][Full Text] [Related]
10. Role of physiologic autoantibody in the removal of senescent human red cells.
Kay MM
J Supramol Struct; 1978; 9(4):555-67. PubMed ID: 108480
[TBL] [Abstract][Full Text] [Related]
11. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations.
Spycher M; Matozan K; Minnig K; Zehnder R; Miescher S; Hoefferer L; Rieben R
Vox Sang; 2009 Nov; 97(4):348-54. PubMed ID: 19656348
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro.
Pollreisz A; Assinger A; Hacker S; Hoetzenecker K; Schmid W; Lang G; Wolfsberger M; Steinlechner B; Bielek E; Lalla E; Klepetko W; Volf I; Ankersmit HJ
Br J Dermatol; 2008 Sep; 159(3):578-84. PubMed ID: 18565176
[TBL] [Abstract][Full Text] [Related]
13. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.
Altznauer F; von Gunten S; Späth P; Simon HU
J Allergy Clin Immunol; 2003 Dec; 112(6):1185-90. PubMed ID: 14657880
[TBL] [Abstract][Full Text] [Related]
14. Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease.
Frostegård AG; Su J; von Landenberg P; Frostegård J
Scand J Rheumatol; 2010; 39(1):77-83. PubMed ID: 20132075
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of alloantibody concentration can predict patient sensitivity to intravenous immunoglobulin desensitization.
Kimball PM; Owens A; Gibney E
Transplantation; 2007 Dec; 84(11):1540-3. PubMed ID: 18091532
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation.
MacMillan HF; Lee T; Issekutz AC
Clin Immunol; 2009 Aug; 132(2):222-33. PubMed ID: 19447680
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis and mechanisms of antibody-mediated hemolysis.
Flegel WA
Transfusion; 2015 Jul; 55 Suppl 2(0):S47-58. PubMed ID: 26174897
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin.
Zhuang Q; Mazer B
J Allergy Clin Immunol; 2001 Aug; 108(2):229-34. PubMed ID: 11496239
[TBL] [Abstract][Full Text] [Related]
20. Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection. An in vivo and in vitro evaluation.
Gautreau C; Kojima T; Woimant G; Cardoso J; Devillier P; Houssin D
Transplantation; 1995 Nov; 60(9):903-7. PubMed ID: 7491691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
